Harrow Health
Harrow Health (NASDAQ: HROW) is a Nashville-based commercial-stage ophthalmic pharmaceutical company that develops, markets, and distributes FDA-approved prescription therapies and specialty compounded medications to eyecare professionals and their patients across North America, generating $272.3M in FY2025 revenue.
- Company typePublic
- Founded2022
- HeadquartersNashville, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Harrow Health does
Harrow Health, Inc. (NASDAQ: HROW) is a Nashville-headquartered, commercial-stage ophthalmic pharmaceutical company that develops, markets, and distributes FDA-approved prescription therapies, branded specialty products, and compounded ophthalmic medications. The company serves eyecare professionals — primarily ophthalmologists and optometrists — and the patients they treat, operating exclusively in North America. Harrow's core commercial portfolio includes VEVYE (cyclosporine ophthalmic solution 0.1% for dry eye disease, $88.7M in FY2025 revenue, up 216% year-over-year), IHEEZO (chloroprocaine hydrochloride ophthalmic gel 3%, a topical anesthetic, $35.9M in Q4 2025 alone), TRIESENCE (triamcinolone acetonide injectable suspension for ocular inflammation), VERKAZIA (cyclosporine ophthalmic emulsion 0.1% for vernal keratoconjunctivitis), and IOPIDINE 1% (aprachlonidine for post-laser intraocular pressure management, with a permanent CMS J-Code J2374 effective July 1, 2026). The portfolio was expanded through the July 2023 acquisition of Santen Pharmaceutical's branded ophthalmic assets and the November 2025 acquisition of Melt Pharmaceuticals, which added the MELT-300 non-opioid procedural sedation platform targeting 2028 approval.
Harrow's commercial model rests on three pillars: a direct enterprise field sales force targeting eyecare prescribers (planned expansion to 100 territories by Memorial Day 2026), distribution through LogiCare3PL for U.S. logistics (effective February 1, 2026), and pharmacy benefit manager formulary placements — most notably the CVS Caremark Tier 1 win for VEVYE that displaced Xiidra effective January 1, 2026. The company also maintains a specialized compounding pharmacy business that provides personalized ophthalmic medications, serving as a foundational revenue stream.
In FY2025, Harrow reported $272.3M in revenue (up 36% year-over-year) and $61.9M in adjusted EBITDA (up 54% year-over-year), with a five-year revenue CAGR above 41% and five-year adjusted EBITDA CAGR above 61%. Management has guided 2026 revenue to $350-365M. Forward growth is supported by a launch pipeline that includes biosimilars (BYOOVIZ in mid-2026, BYQLOVI in Q2 2026, OPUVIZ in January 2027), a TRIESENCE Phase 3 trial in cataract surgery (approximately 250 patients), and the VERKAZIA re-launch for vernal keratoconjunctivitis. The company is publicly traded with institutional ownership around 72.76% as of Q1 2026, a $1.46B-$1.58B market capitalization, and is led by founder and CEO Mark L. Baum.
Harrow Health firmographics
Firmographics- Name
- Harrow Health
- Legal name
- Harrow, Inc.
- Website
- https://harrowinc.com
- Company type
- Public
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Harrow Health (NASDAQ: HROW) is a Nashville-based commercial-stage ophthalmic pharmaceutical company that develops, markets, and distributes FDA-approved prescription therapies and specialty compounded medications to eyecare professionals and their patients across North America, generating $272.3M in FY2025 revenue.
- Ownership category
- akta.pro rank
Harrow Health industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industries
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Rare Ophthalmology Disorder Therapies (HLAIAIAK), Specialty Care Pharmaceuticals (HLAIAAAB), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
Keywords
Where Harrow Health is headquartered
LocationHeadquarters
- HQ city
- Nashville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Harrow Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
Revenue model
- Branded Pharmaceutical Products: Revenue from sale of FDA-approved prescription ophthalmic drugs including VEVYE, IHEEZO, TRIESENCE, VERKAZIA, and IOPIDINE 1%. These are sold through pharmacies and distributed to eyecare professionals and patients.
- Compounding Pharmacy: Specialized compounding business providing personalized ophthalmic medications, serving as a foundational component of Harrow's product portfolio and revenue base.
- Biosimilar Products: Revenue from upcoming biosimilar launches including BYOOVIZ (mid-2026) and OPUVIZ (January 2027), expanding product portfolio into biosimilar market segment.
- Acquisition Integration: Revenue growth driven by strategic acquisitions including Santen Pharmaceutical's branded ophthalmic portfolio (July 2023) and Melt Pharmaceuticals (November 2025), expanding product offerings and market presence.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Harrow Health product offering
Product offeringCore offering
Harrow Health is a commercial-stage eye health pharmaceutical company that develops, acquires, and markets FDA-approved branded prescription ophthalmic therapies. Its portfolio includes VEVYE, IHEEZO, TRIESENCE, VERKAZIA, and IOPIDINE 1%, addressing dry eye, ocular anesthesia, inflammation, vernal keratoconjunctivitis, and intraocular pressure. The company also operates a specialized ophthalmic compounding pharmacy business and is developing non-opioid procedural sedation (MELT-300) and biosimilars.
Product overview
Harrow Health operates as an ophthalmic pharmaceutical company with a diversified portfolio of branded therapies, acquired products, and pipeline assets. The core commercial portfolio includes VEVYE (dry eye treatment), IHEEZO (anesthetic gel), TRIESENCE (corticosteroid for ocular inflammation), VERKAZIA (for vernal keratoconjunctivitis), and IOPIDINE 1% (for intraocular pressure). The company also holds acquired brands from Santen Pharmaceutical (urology/panuveitis treatments) and has expanded into non-opioid sedation through the Melt Pharmaceuticals acquisition. Pipeline products include planned biosimilars BYOOVIZ and OPUVIZ. The portfolio addresses various ophthalmic conditions including dry eye disease, ocular inflammation, allergic eye disease, and procedural sedation.
Differentiator
Problem solved
Functional benefit
Brands
- Harrow IP, LLC: Subsidiary entity holding Harrow's registered trademarks
Products and services
- VEVYE (cyclosporine ophthalmic solution 0.1%) FDA-approved prescription therapy for dry eye disease. Generated $88.7M full-year revenue in 2025, up 216% year-over-year.
- IHEEZO (chloroprocaine hydrochloride ophthalmic gel 3%)
- TRIESENCE (triamcinolone acetonide injectable suspension) Corticosteroid injectable suspension for the treatment of ocular inflammation. Phase 3 trial underway to expand label to all cataract surgery patients.
- VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% FDA-approved calcineurin inhibitor immunomodulator for vernal keratoconjunctivitis (VKC), a serious allergic eye disease primarily affecting children. First FDA-approved steroid-sparing therapy for VKC.
- IOPIDINE 1%
- MELT-300 Non-opioid, non-IV procedural sedation therapy aimed at transforming procedural sedation and reducing opioid exposure.
- BYOOVIZ (planned biosimilar) Planned biosimilar launch for mid-2026, expanding Harrow's portfolio into the biosimilar market segment.
- OPUVIZ (planned biosimilar) Planned biosimilar launch for January 2027, expanding Harrow's biosimilar portfolio.
- BYQLOVI (planned product) Planned product launch for Q2 2026.
- Santen Pharmaceutical Branded Ophthalmic Portfolio (acquired) Acquired Japanese pharmaceutical firm's branded ophthalmic portfolio specializing in uveitis and panuveitis treatments, strengthening Harrow's North American commercial footprint.
- Ophthalmic Compounding Pharmacy Services
Quantifiable outcome
- VEVYE reduces severe IOP spikes after laser procedures from 23% to 2% (91% relative risk reduction)
- +3 more outcomes
Companies that use Harrow Health
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Harrow Health technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Harrow Health partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- LogiCare3PLcoreLogiCare3PL was selected as Harrow's U.S. distribution partner for its portfolio of ophthalmic disease management solutions, effective February 1, 2026. LogiCare3PL provides both non-title and 3PL title distribution services, successfully onboarding Harrow within four weeks to meet rapid market readiness timelines. Both organizations anticipate continued collaboration as Harrow expands its product offerings across the U.S. market.
- Melt PharmaceuticalscoreHarrow completed the acquisition of Melt Pharmaceuticals, a company specializing in non-opioid, non-IV sedation therapies. Melt's product portfolio includes MELT-300, which aims to transform procedural sedation and reduce opioid exposure, with plans for further clinical development and regulatory approval by 2028. The acquisition expands Harrow's portfolio into new therapeutic areas.
- Santen Pharmaceutical Co. Ltd.coreHarrow acquired Santen Pharmaceutical Co. Ltd.'s branded ophthalmic portfolio in July 2023. Santen is a Japanese pharmaceutical firm specializing in uveitis and panuveitis treatments. The acquisition broadened Harrow's product portfolio and strengthened its commercial footprint across North America in the ophthalmic pharmaceutical market.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Harrow Health competitors and assessment
Company assessmentDirect peers
- Bausch + Lomb: Bausch + Lomb is a global eye-health company with a broad ophthalmic pharmaceutical and surgical portfolio. It directly competes with Harrow across dry eye, inflammation, and surgical adjunct categories, with a similarly diversified branded eyecare franchise.
- Alcon: Alcon is a leading eyecare company spanning surgical, vision care, and ophthalmic pharmaceuticals. It overlaps with Harrow in prescription ophthalmics and competes for PBM and physician relationships across dry eye and surgical adjuncts.
- Sun Pharmaceutical Industries: Sun Pharma's specialty/ophthalmic division markets branded and generic ophthalmic products, including dry-eye therapies. It is comparable to Harrow's specialty pharma and compounding roots and competes for the same eyecare prescriber base.
- Amneal Pharmaceuticals: Amneal has a specialty/generics business with growing ophthalmic and complex therapeutic offerings, including biosimilars. It is comparable to Harrow in combining specialty pharma with a developing biosimilar pipeline targeting the same payer channels.
Broad incumbents
- AbbVie (Allergan Aesthetics / Eye Care): AbbVie's Allergan heritage includes the Restasis franchise and a deep ophthalmic pipeline. As a broad incumbent, it competes head-to-head with Harrow in dry eye while bringing significantly larger commercial and R&D resources.
- Novartis (Ophthalmology): Novartis operates a sizable ophthalmology franchise including Lucentis and dry-eye assets. As a broad incumbent, it competes with Harrow across multiple ophthalmic indications and is comparable in therapeutic focus if not in scale.
Emerging players
- Ocular Therapeutix: Ocular Therapeutix is a biopharmaceutical company focused on ophthalmic diseases, with commercial and pipeline assets in dry eye and post-surgical inflammation. It is comparable to Harrow as a smaller, ophthalmic-focused commercial-stage company.
- EyePoint Pharmaceuticals: EyePoint Pharmaceuticals develops sustained-release ocular therapies for retinal and other eye diseases. It is comparable to Harrow as a focused ophthalmic drug developer targeting similar eyecare specialists, though smaller in commercial scale.
- Tarsus Pharmaceuticals: Tarsus Pharmaceuticals is a commercial-stage ophthalmic company with a lead product in eye-care (e.g., Demodex blepharitis). It is comparable to Harrow as a specialty eyecare pharma company building category-defining franchises.
- Apellis Pharmaceuticals: Apellis markets ophthalmic therapies for retinal diseases and has expanded into earlier segments of eye care. It is comparable to Harrow as a focused commercial-stage ophthalmic biopharma with branded, specialty-distributed products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Harrow Health social profiles
Digital presenceHarrow Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Harrow Health leadership team
Management profileNumber of profiles
Profiles4 records
Harrow Health subsidiaries and ownership
Company hierarchySubsidiaries3 records
Harrow Health funding detail
Funding detailFunding overview
Funding rounds9 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Harrow Health M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Harrow Health
What does Harrow Health do?
Harrow Health is a commercial-stage eye health pharmaceutical company that develops, acquires, and markets FDA-approved branded prescription ophthalmic therapies. Its portfolio includes VEVYE, IHEEZO, TRIESENCE, VERKAZIA, and IOPIDINE 1%, addressing dry eye, ocular anesthesia, inflammation, vernal keratoconjunctivitis, and intraocular pressure. The company also operates a specialized ophthalmic compounding pharmacy business and is developing non-opioid procedural sedation (MELT-300) and biosimilars.
Is Harrow Health a public or private company?
Harrow Health is a public company. It is classified as public and is currently operating.
When was Harrow Health founded?
Harrow Health was founded in 2022. It employs 251 to 500 people.
Where is Harrow Health based?
Harrow Health is headquartered in Nashville, United States, in the North America region.
How does Harrow Health make money?
Four revenue lines are on record. Branded Pharmaceutical Products are the primary driver. The others are compounding Pharmacy, biosimilar Products and acquisition Integration.
Who are Harrow Health's main competitors?
Direct peers on record are Bausch + Lomb, Alcon, Sun Pharmaceutical Industries and Amneal Pharmaceuticals. Broad incumbents are AbbVie (Allergan Aesthetics / Eye Care) and Novartis (Ophthalmology). Emerging players are Ocular Therapeutix, EyePoint Pharmaceuticals, Tarsus Pharmaceuticals and Apellis Pharmaceuticals.
Does Harrow Health have an API?
No public API is recorded for Harrow Health.
What industry is Harrow Health in?
Harrow Health's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its SIC code is 2834.